News: Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

271.42USD
12:55pm EDT
Price Change (% chg)

$-6.87 (-2.47%)
Prev Close
$278.29
Open
$277.64
Day's High
$277.64
Day's Low
$271.36
Volume
68,696
Avg. Vol
220,530
52-wk High
$283.00
52-wk Low
$131.50

Search Stocks
Select another date:

Thu, May 30 2013

UK cost agency recommends Bayer, Regeneron eye drug

LONDON, May 31 - Britain's healthcare cost watchdog NICE is recommending a new eye drug from Bayer and Regeneron, after a price discount was offered for its use on the state health service.

Regeneron settles all pending litigation with Roche's Genentech

May 20 - Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug, Eylea, and cancer drug, Zaltrap.

FEATURE-Fast climbing biotech Regeneron still has room to grow

* Shares jump five-fold in two years, market value $26 bln

UPDATE 2-Regeneron raises Eylea sales view, shares hit all-time high

* Shares hit life-high of $270 (Adds comments from conference call, analyst comment)

Regeneron raises 2013 Eylea sales view, profit beats Street

- Regeneron Pharmaceuticals Inc's first-quarter results beat analysts' estimates for the seventh straight quarter as sales of its eye drug Eylea continued to gather pace, and the company raised its 2013 sales estimate for the drug.

Regeneron raises 2013 Eylea sales view, profit beats Street

May 3 - Regeneron Pharmaceuticals Inc's first-quarter results beat analysts' estimates for the seventh straight quarter as the sales of its eye drug Eylea continued to gather pace, and the company raised its 2013 sales estimate for the drug.

UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea

May 1 - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.

BRIEF-Regeneron Pharma shares resume trading, up 16 percent

NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares resume trading, up 16 percent * Shares as shares of Allergan slide after co says vision drug approval

BRIEF-Regeneron Pharma shares halted, last up 14.3 pct

NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares halted, last up 14.3 percent

BRIEF-Regeneron Pharma shares up 2.8 pct after the bell

NEW YORK, April 24 - Regeneron Pharmaceuticals Inc : * Shares up 2.8 percent after the bell, to join S&P 500 next week

Select another date:
Search Stocks